OMER250117P16000
- 4.30
- 0.000.00%
Omeros Newsroom
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
D. Boral Capital Initiates Omeros(OMER.US) With Buy Rating, Announces Target Price $36
Omeros Initiated at Buy by D. Boral Capital
Express News | D. Boral Capital Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $36
Needham Maintains Omeros(OMER.US) With Hold Rating
Omeros (OMER) Gets a Hold From Needham
Needham Reiterates Hold on Omerosto Hold
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Sector Update: Health Care Stocks Lower Thursday Afternoon
Top Midday Gainers
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant
Gold Falls Sharply, Lamb Weston Shares Plunge
Omeros Stock Gains 52% On Successful Trial Results
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
Omeros Up Over 66%, On Track for Highest Close Since September 2021 -- Data Talk
Omeros' Pivotal Trial of Narsoplimab Meets Primary Endpoint
Express News | Omeros Corp: To Resubmit a Bla to FDA for Narsoplimab
Express News | Omeros' Narsoplimab Meets Its Pivotal Trial Primary Endpoint
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges